High-content, arrayed compound screens with rhinovirus, influenza A virus and herpes simplex virus infections.
Journal
Scientific data
ISSN: 2052-4463
Titre abrégé: Sci Data
Pays: England
ID NLM: 101640192
Informations de publication
Date de publication:
08 10 2022
08 10 2022
Historique:
received:
15
05
2022
accepted:
28
09
2022
entrez:
8
10
2022
pubmed:
9
10
2022
medline:
12
10
2022
Statut:
epublish
Résumé
Viruses are genetically and structurally diverse, and outnumber cells by orders of magnitude. They can cause acute and chronic infections, suppress, or exacerbate immunity, or dysregulate survival and growth of cells. To identify chemical agents with pro- or antiviral effects we conducted arrayed high-content image-based multi-cycle infection screens of 1,280 mainly FDA-approved compounds with three human viruses, rhinovirus (RV), influenza A virus (IAV), and herpes simplex virus (HSV) differing in genome organization, composition, presence of an envelope, and tropism. Based on Z'-factors assessing screening quality and Z-scores ranking individual compounds, we identified potent inhibitors and enhancers of infection: the RNA mutagen 5-Azacytidine against RV-A16; the broad-spectrum antimycotic drug Clotrimazole inhibiting IAV-WSN; the chemotherapeutic agent Raltitrexed blocking HSV-1; and Clobetasol enhancing HSV-1. Remarkably, the topical antiseptic compound Aminacrine, which is clinically used against bacterial and fungal agents, inhibited all three viruses. Our data underscore the versatility and potency of image-based, full cycle virus propagation assays in cell-based screenings for antiviral agents.
Identifiants
pubmed: 36209289
doi: 10.1038/s41597-022-01733-4
pii: 10.1038/s41597-022-01733-4
pmc: PMC9547564
doi:
Substances chimiques
Anti-Infective Agents, Local
0
Antiviral Agents
0
Mutagens
0
Aminacrine
78OY3Z0P7Z
Clobetasol
ADN79D536H
Clotrimazole
G07GZ97H65
Azacitidine
M801H13NRU
Types de publication
Dataset
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
610Subventions
Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation)
ID : National Research Program
Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation)
ID : 316030_170799 / 1
Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation)
ID : 31003A_179256 / 1
Informations de copyright
© 2022. The Author(s).
Références
Antiviral Res. 2004 Feb;61(2):73-81
pubmed: 14670580
Clin Microbiol Rev. 2016 Jul;29(3):695-747
pubmed: 27281742
Lancet. 2003 Jan 4;361(9351):51-9
pubmed: 12517470
Sci Data. 2020 Aug 12;7(1):265
pubmed: 32788590
Cell Death Dis. 2018 Feb 15;9(3):272
pubmed: 29449668
Molecules. 2021 Feb 04;26(4):
pubmed: 33557246
Nat Commun. 2018 May 17;9(1):1980
pubmed: 29773792
Clin Microbiol Rev. 2013 Jan;26(1):135-62
pubmed: 23297263
J Gastroenterol Hepatol. 2006 Nov;21(11):1758-60
pubmed: 16984606
Semin Cell Dev Biol. 2017 Aug;68:59-71
pubmed: 28506891
Future Virol. 2018 Jul;13(7):505-518
pubmed: 30245735
Cell Rep. 2017 Nov 14;21(7):1737-1745
pubmed: 29141209
Infect Agent Cancer. 2014 Jan 20;9(1):3
pubmed: 24438207
J Biomol Screen. 1999;4(2):67-73
pubmed: 10838414
Cell Rep. 2021 Apr 6;35(1):108959
pubmed: 33811811
Sci Signal. 2008 Jul 22;1(29):re8
pubmed: 18648074
J Cell Sci. 2020 Nov 9;134(5):
pubmed: 32917739
Science. 2021 Jul 30;373(6554):541-547
pubmed: 34326236
Science. 2018 Apr 6;360(6384):
pubmed: 29622628
J Clin Virol. 2003 Jan;26(1):29-37
pubmed: 12589832
Cell. 1991 Oct 4;67(1):117-30
pubmed: 1913813
Antimicrob Agents Chemother. 2018 Sep 24;62(10):
pubmed: 30104269
Virol J. 2010 Oct 11;7:264
pubmed: 20937137
J Virol. 2014 Nov;88(22):13029-46
pubmed: 25165113
J Clin Microbiol. 1998 Feb;36(2):539-42
pubmed: 9466772
J Infect. 2017 Jun;74 Suppl 1:S41-S46
pubmed: 28646961
J Pharmacol Toxicol Methods. 2014 Jan-Feb;69(1):9-16
pubmed: 24103906
J Virol. 2010 Apr;84(8):3808-24
pubmed: 20106923
Antimicrob Agents Chemother. 2020 Aug 20;64(9):
pubmed: 32601166
Biol Chem. 2019 Dec 18;401(1):31-46
pubmed: 31408430
J Virol. 2022 Jan 26;96(2):e0106021
pubmed: 34705560
Nat Commun. 2021 Jun 3;12(1):3309
pubmed: 34083527
Arch Virol. 2020 Mar;165(3):793-797
pubmed: 31980941
PLoS One. 2015 Sep 28;10(9):e0138760
pubmed: 26413745
J Pharmacol Toxicol Methods. 2015 Jan-Feb;71:1-7
pubmed: 25464019
Curr Res Virol Sci. 2022;3:100019
pubmed: 35072124